Aktuellt
SENASTE
Redeye is impressed by the continuous efforts in optimizing the potential for Episealer as the company is now initiating product development for its implant intended for the MTP-1 joint. In the press release, Episurf Medical stated that it has the ambition to file a 510(k) application for the US market in late 2022 or H1 2023. The US could be accessed already next year, however, with its patellofemoral implant system.
LÄS MER
